150 related articles for article (PubMed ID: 9484665)
1. Serum chromogranin A: early detection of hormonal resistance in prostate cancer patients.
Wu JT; Astill ME; Liu GH; Stephenson RA
J Clin Lab Anal; 1998; 12(1):20-5. PubMed ID: 9484665
[TBL] [Abstract][Full Text] [Related]
2. Serum chromogranin-A in advanced prostate cancer.
Ferrero-Poüs M; Hersant AM; Pecking A; Brésard-Leroy M; Pichon MF
BJU Int; 2001 Nov; 88(7):790-6. PubMed ID: 11890255
[TBL] [Abstract][Full Text] [Related]
3. Circulating neuroendocrine markers in patients with prostate carcinoma.
Berruti A; Dogliotti L; Mosca A; Bellina M; Mari M; Torta M; Tarabuzzi R; Bollito E; Fontana D; Angeli A
Cancer; 2000 Jun; 88(11):2590-7. PubMed ID: 10861438
[TBL] [Abstract][Full Text] [Related]
4. Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy.
Wu JT; Wu TL; Chang CP; Tsao KC; Sun CF
J Clin Lab Anal; 1999; 13(6):308-11. PubMed ID: 10633300
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
6. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate.
Angelsen A; Syversen U; Stridsberg M; Haugen OA; Mjølnerød OK; Waldum HL
Prostate; 1997 May; 31(2):110-7. PubMed ID: 9140124
[TBL] [Abstract][Full Text] [Related]
7. Cross-correlation of serum chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis.
Ahel MZ; Kovacic K; Tarle M
Anticancer Res; 2001; 21(2B):1363-6. PubMed ID: 11396214
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.
Chuang CK; Wu TL; Tsao KC; Liao SK
J Formos Med Assoc; 2003 Jul; 102(7):480-5. PubMed ID: 14517586
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer.
Hvamstad T; Jordal A; Hekmat N; Paus E; Fosså SD
Eur Urol; 2003 Aug; 44(2):215-21. PubMed ID: 12875941
[TBL] [Abstract][Full Text] [Related]
11. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
Lilleby W; Paus E; Skovlund E; Fosså SD
Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
[TBL] [Abstract][Full Text] [Related]
13. The chromogranin-A (CgA) in prostate cancer.
Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
[TBL] [Abstract][Full Text] [Related]
14. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
Baudin E; Gigliotti A; Ducreux M; Ropers J; Comoy E; Sabourin JC; Bidart JM; Cailleux AF; Bonacci R; Ruffié P; Schlumberger M
Br J Cancer; 1998 Oct; 78(8):1102-7. PubMed ID: 9792158
[TBL] [Abstract][Full Text] [Related]
15. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.
Berruti A; Dogliotti L; Mosca A; Gorzegno G; Bollito E; Mari M; Tarabuzzi R; Poggio M; Torta M; Fontana D; Angeli A
Ann Oncol; 2001; 12 Suppl 2():S153-7. PubMed ID: 11762344
[TBL] [Abstract][Full Text] [Related]
16. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients.
Tarle M; Ahel MZ; Kovacić K
Anticancer Res; 2002; 22(4):2525-9. PubMed ID: 12174956
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
18. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas.
Tsao KC; Wu JT
Clin Chim Acta; 2001 Nov; 313(1-2):21-9. PubMed ID: 11694235
[TBL] [Abstract][Full Text] [Related]
19. Plasma chromogranin A in patients with prostate cancer improves the diagnostic efficacy of free/total prostate-specific antigen determination.
Fracalanza S; Prayer-Galetti T; Pinto F; Navaglia F; Sacco E; Ciaccia M; Plebani M; Pagano F; Basso D
Urol Int; 2005; 75(1):57-61. PubMed ID: 16037709
[TBL] [Abstract][Full Text] [Related]
20. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
